[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-354397-en":59,"doc-seo-354397-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":73,"language":74,"language_code":75,"site_id":76,"html_lang":75,"table_of_contents":77,"faqs":78,"seo_title":79,"seo_description":66,"update_tm":80,"read_time":41,"preview_page_count":19,"preview_urls":81},354397,2336478951081,"Ben ","https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer - Original Article","Accurate identification of individuals at high risk of gastric cancer (GC) is critical for effective screening, yet remains challenging. Plasma proteomic signatures were identified and used to build a GC risk prediction model for stratification. Discovery profiling used liquid chromatography–tandem mass spectrometry in 100 GC cases and 94 controls, then proteins were evaluated in 52,552 UK Biobank participants with 13.63 years median follow-up, using LASSO-penalized Cox regression with stability selection and bootstrap internal validation.","Gastric Cancer (2026) 29:725–736  \n[https://doi.org/10.1007/s10120-026-01749-4](https://doi.org/10.1007/s10120-026-01749-4)  \nORIGINAL ARTICLE  \nPlasma proteomic signatures improve risk stratification and personalized screening for gastric cancer  \nXue Li1,2 · Wen-Hao Shi3 · Juan Zhu1,2 · Ying Chen1,4 · Bin Liu5 · Nai-Ren Zheng6 · Le Wang1,2 · Li Yuan2,7 · Ying-Ying Mao5 · Xiang-Dong Cheng1,2,8 · Ling-Bin Du1,2  \nReceived: 22 January 2026 / Accepted: 14 April 2026 / Published online: 14 May 2026 © The Author(s) 2026, modified publication 2026  \nAbstract  \nBackground Accurate identification of individuals at high risk of gastric cancer (GC) remains a major challenge for effective screening. We aimed to identify plasma proteomic signatures and develop a risk prediction model for GC risk stratification. Methods Plasma proteomic profiling was performed using liquid chromatography–tandem mass spectrometry in a case– control discovery set (100 GC cases and 94 controls). Candidate proteins were evaluated in 52,552 UK Biobank participants with a median follow-up of 13.63 years, during which 92 incident GC cases were identified. Risk models integrating clinical, genetic, and proteomic factors were developed using LASSO-penalized Cox regression with stability selection and internally validated using bootstrap resampling.  \nResults Among 2306 differentially expressed proteins in discovery, 25 were replicated in validation at nominal significance (P\u003C 0.05) with consistent directions. Two proteins (CTSD and GGH) remained significant after false discovery rate correction. A primary proteomic model (clinical factors plus five proteins) improved discrimination versus clinical model (optimism-corrected C-index: 0.745 vs. 0.732, P = 0.046). Risk stratification revealed a clear GC risk gradient: hazard ratios were 6.08 (95% CI 2.15–17.20) for moderate-risk and 23.88 (95% CI 8.66–65.87) for high-risk groups. The risk score was also associated with GC risk as continuous variable (HR per standard deviation: 1.09, 95% CI 1.08–1.11) . The 15-year cumulative incidence ranged from 0.02 to 0.56% across risk groups. Decision curve analysis indicated improved clinical utility. Conclusions Plasma proteomic signatures may improve GC risk stratification beyond traditional clinical factors and could support more targeted screening strategies. Further validation is warranted.  \nKeywords Gastric cancer · Proteomics · Biomarker · Cancer screening · Cancer prevention  \nXue Li, Wen-Hao Shi, Juan Zhu, Ying Chen and Bin Liu have equally contributed to this work.  \n􀀍 Ling-Bin Du[dulb@zjcc.org.cn](dulb@zjcc.org.cn)  \n1 Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China  \n2 Zhejiang Key Laboratory of Prevention, Diagnosis and Therapy for Gastrointestinal Cancer, Hangzhou 310022, Zhejiang, China  \n3 Analysis Center, Chemistry Department, Tsinghua University, Beijing 100084, China  \n4 Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, China  \n5 Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China  \n6 Beijing Pineal Diagnostics Company Limited, Beijing 102206, China  \n7 Department of Integrated Chinese and Western Medicine, Zhejiang Cancer Hospital , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China  \n8 Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China  \nIntroduction  \nGastric cancer presents a significant global health burden, ranking among the top five most prevalent cancers worldwide [1], with particularly high incidence rates in developing countries [2]. Contributing factors to this elevated incidence include Helicobacter pylori infection, tobacco use, alcohol consumption, dietary habi","cbCaia3PKIZ9HUPm","https://ap.wps.com/l/cbCaia3PKIZ9HUPm","pdf",3547702,16,12,"English","en",105,"# Abstract\n## Background and objective\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What was the primary goal of this study on gastric cancer screening?\",\"answer\":\"To identify plasma proteomic signatures and develop a risk prediction model to improve GC risk stratification and enable more personalized screening.\"},{\"question\":\"How were plasma proteomic signatures discovered and validated?\",\"answer\":\"Proteomic profiling was performed using liquid chromatography–tandem mass spectrometry in a case–control discovery set, then candidate proteins were evaluated in 52,552 UK Biobank participants with long-term follow-up.\"},{\"question\":\"Which proteomic model improvements were reported compared with clinical-only risk models?\",\"answer\":\"A primary proteomic model (clinical factors plus five proteins) showed better discrimination than the clinical model, with optimism-corrected C-index values of 0.745 vs 0.732 and a reported significance level.\"}]","Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer - Original Article | PDF",1790110437,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67cc08db2571923d45ebf98f8f201eff.webp",983,1305,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06fb96af0f7023a54495a3c831a17576.webp",982,1304,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6ca028521aa564bfbb17061e200912f.webp",981,1303,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6c8ec4669d89f068ac3420bb88d2c05.webp",980,1301,{"code":4,"msg":100,"data":101},"ok",{"site_id":76,"language":75,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"plasma-proteomic-signatures-improve-risk-stratification-and-personalized-screening-for-gastric-cancer-original-article","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/plasma-proteomic-signatures-improve-risk-stratification-and-personalized-screening-for-gastric-cancer-original-article/354397/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":75,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/plasma-proteomic-signatures-improve-risk-stratification-and-personalized-screening-for-gastric-cancer-original-article/354397.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":72},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What was the primary goal of this study on gastric cancer screening?","Question",{"text":146,"@type":147},"To identify plasma proteomic signatures and develop a risk prediction model to improve GC risk stratification and enable more personalized screening.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How were plasma proteomic signatures discovered and validated?",{"text":151,"@type":147},"Proteomic profiling was performed using liquid chromatography–tandem mass spectrometry in a case–control discovery set, then candidate proteins were evaluated in 52,552 UK Biobank participants with long-term follow-up.",{"name":153,"@type":144,"acceptedAnswer":154},"Which proteomic model improvements were reported compared with clinical-only risk models?",{"text":155,"@type":147},"A primary proteomic model (clinical factors plus five proteins) showed better discrimination than the clinical model, with optimism-corrected C-index values of 0.745 vs 0.732 and a reported significance level.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":76},1790334150]